GSK has turned to China’s Hansoh Pharma to add another antibody-drug conjugate (ADC) to its oncology pipeline, this time licensing a B7-H3-targeting candidate for $185 million upfront
GSK has said that a regimen of PD-1 inhibitor Jemperli with PARP inhibitor Zejula has shown efficacy in the second stage of the RUBY trial, which could open up wider use i
A year after GSK pulled its BCMA-targeting antibody-drug conjugate (ADC) Blenrep from the US market as a later-line therapy for multiple myeloma, there are signs that the
Sosei Heptares has lost GSK as a partner for an inflammatory bowel disease (IBD) drug candidate GSK4381406, but says it will take the programme forward as it has significa
GSK has developed a new propellant technology for inhaler devices that drastically reduces their use of greenhouse gases, which perhaps surprisingly account for nearly hal
